CMAJ • April 28, 2009; 180 (9). doi:10.1503/cmaj.081545.
© 2009 Canadian Medical Association or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
This Article
Right arrow Abstract
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Résumé
Right arrow Online Appendix
Right arrow Submit a response
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ko, G. T.C.
Right arrow Articles by Chan, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ko, G. T.C.
Right arrow Articles by Chan, J. C.
Related Collections
Right arrowRelated Articles

Effect of interactions between C peptide levels and insulin treatment on clinical outcomes among patients with type 2 diabetes mellitus

Gary T.C. Ko, MD, Wing-Yee So, MD, Peter C. Tong, PhD, Wing-Bun Chan, MBChB, Xilin Yang, PhD, Ronald C. Ma, MBBChir, Alice P. Kong, MBChB, Risa Ozaki, MBBS, Chun-Yip Yeung, MBBS, Chun-Chung Chow, MBBS and Juliana C. Chan, MD

From the Department of Medicine and Therapeutics, Chinese University of Hong Kong (So, Tong, Yang, Ma, Kong, Ozaki, Yeung, Chow, J. Chan), the Hong Kong Institute of Diabetes and Obesity (Ko, Tong, J. Chan), and the Qualigenics Clinic (W. Chan), Hong Kong, China


Figure 111
View larger version (19K):
[in this window]
[in a new window]

  		Figure 1: Clinical outcomes of 503 patients with type 2 diabetes mellitus stratified by baseline fasting C peptide levels and status of insulin use. Analysis of variance for comparison of the 4 groups:p < 0.001.

 

Figure 211
View larger version (20K):
[in this window]
[in a new window]

  		Figure 2: Incidence of death (top panel) and new-onset cardiovascular disease (bottom panel) among 503 patients with type 2 diabetes, by baseline fasting C peptide level and insulin use. Note: I+ = insulin use, I– = no insulin use, CP+ = normal to high C peptide level, CP– = low C peptide level.

 

View this table:
[in this window]
[in a new window]

  		Table 1: Independent factors associated with outcomes

 

View this table:
[in this window]
[in a new window]

  		Table 2: Subgroup analysis of independent factors associated with outcomes